<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>250-ANTI-LYMPHOCYTE-GLOBULINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>250-ANTI-LYMPHOCYTE-GLOBULINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general illness. This risk is increased in older patients already immunodepressed by the underlying disease.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>In particular, use an inactivated vaccine when one exists (poliomyelitis)</COMMENT>
</INTERACTION>
</INTERACTIONS>
